131 related articles for article (PubMed ID: 37327528)
1. Clinical effectiveness and safety of edoxaban in obese patients - Results of the prospective Dresden NOAC Registry (NCT01588119).
Tittl L; Köhler C; Marten S; Naue C; Fache K; Stannek L; Schreier T; Beyer-Westendorf J
Thromb Res; 2023 Aug; 228():134-136. PubMed ID: 37327528
[No Abstract] [Full Text] [Related]
2. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Tittl L; Endig S; Marten S; Reitter A; Beyer-Westendorf I; Beyer-Westendorf J
Int J Cardiol; 2018 Jul; 262():85-91. PubMed ID: 29622509
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
[TBL] [Abstract][Full Text] [Related]
4. Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY.
Beyer-Westendorf J; Marten S; Naue C; Tittl L; Hänsel U; Beyer-Westendorf I; Mizera H; Schreier T; Festerling E; Reitter A; Spindler M; Bornhäuser M
Thromb Res; 2020 Jun; 190():91-98. PubMed ID: 32335423
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119).
Beyer-Westendorf J; Marten S; Naue C; Tittl L; Sockel K; Middecke JM; Bornhäuser M
Thromb Res; 2020 Jul; 191():50-55. PubMed ID: 32387685
[No Abstract] [Full Text] [Related]
6. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry.
Kim JY; Choi EK; Lim HE; Oh YS; Cho Y; On YK
J Korean Med Sci; 2022 Dec; 37(48):e335. PubMed ID: 36513051
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.
Briasoulis A; Mentias A; Mazur A; Alvarez P; Leira EC; Vaughan Sarrazin MS
Cardiovasc Drugs Ther; 2021 Apr; 35(2):261-272. PubMed ID: 33404923
[TBL] [Abstract][Full Text] [Related]
11. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Beyer-Westendorf J; Förster K; Pannach S; Ebertz F; Gelbricht V; Thieme C; Michalski F; Köhler C; Werth S; Sahin K; Tittl L; Hänsel U; Weiss N
Blood; 2014 Aug; 124(6):955-62. PubMed ID: 24859362
[TBL] [Abstract][Full Text] [Related]
12. Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry.
Bertomeu-Gonzalez V; Moreno-Arribas J; Esteve-Pastor MA; Roldán-Rabadán I; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
J Am Heart Assoc; 2020 Jan; 9(1):e013789. PubMed ID: 31870235
[TBL] [Abstract][Full Text] [Related]
13. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation.
Yao X; Inselman JW; Ross JS; Izem R; Graham DJ; Martin DB; Thompson AM; Ross Southworth M; Siontis KC; Ngufor CG; Nath KA; Desai NR; Nallamothu BK; Saran R; Shah ND; Noseworthy PA
Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e006515. PubMed ID: 33012172
[TBL] [Abstract][Full Text] [Related]
15. [Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin].
Yavelov IS
Kardiologiia; 2020 Sep; 60(8):124-129. PubMed ID: 33155968
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale.
Önsel Türk U; Alioğlu E; Mavioğlu Z; Diker E; Özpelit E; De Caterina R
Turk Kardiyol Dern Ars; 2022 Mar; 50(2):117-123. PubMed ID: 35400633
[TBL] [Abstract][Full Text] [Related]
17. Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
Li X; Zuo C; Ji Q; Xue Y; Wang Z; Lv Q
Drug Des Devel Ther; 2021; 15():1931-1943. PubMed ID: 33986592
[TBL] [Abstract][Full Text] [Related]
18. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2021 Jun; 202():24-30. PubMed ID: 33711755
[TBL] [Abstract][Full Text] [Related]
19. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen J; Zhuang X; Long M; Su C; Wang L
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
